Benefits and monetised risks of applications for authorisations

Workshop on Socio-Economic Analysis in AfAs and Restrictions under REACH

Sanna Henrichson

Risk Management Implementation

European Chemicals Agency

Meta-analysis on benefits and monetised risks of authorisations

- The purpose is to improve our understanding of the benefits and monetised risks of the continued use of Annex XIV substances applied for
- Preliminary analysis done on 52 uses (80% DU) that have been through the opinion development process
- Information gathered from applications and opinions of the committees on:
  - Monetised risks and benefits
  - Review period applied for and recommended
- Values annualised and aggregated to facilitate overall comparison of benefits and monetised risks

The application process is delivering on its aims

- Substitution is taking place
  - No applications received for over 30% of Annex XIV substances by latest application date
  - For 19 uses, applicants only requested the necessary time to substitute the SVHC with a safer alternative
  - Anecdotal evidence of companies that have found substitutes after starting preparing an application
- The risks have reduced
  - Applicants have implemented risk management measures to reduce exposure (e.g. Sasol Huntsman) and imposed requirements on their DUs (e.g. Blue Cube)
  - Furthermore, RAC have recommended additional conditions and monitoring arrangements

Costs and benefits of authorisation: preliminary results (work in progress)

- Applicants estimated the average benefit of authorised use at €50m per year
  - SEAC considered that some benefit categories were not relevant (ref. Employment): benefits around €10m per year
- Applicants estimated the average monetised risks of authorized use at €0.14m per year
  - This was considered somewhat lower by RAC and SEAC
- Methodological issues were identified:
  - Many applicants view costs of non use high (cf. employment)…
  - … but have difficulties in analyzing the impacts for the whole supply chain
  - With dose-response functions made public in advance, monetised risks were estimated…
  - … still prone to over or under estimations (e.g. man via the environment)

The length of the review period depends on technical and scientific arguments



Thank you!

Sanna.henrichson@echa.europa.eu

Subscribe to our news at
echa.europa.eu/subscribe

Follow us on Twitter
@EU_ECHA

Follow us on Facebook
Facebook.com/EUECHA